Table 2.

Overview of treatment emergent AEs

	rIX-FP, N (%) E
	Prophylaxis	On demand	Total
Number of subjects	13	4	17
AE leading to study withdrawal	0	0	0
Serious AEs (SAEs)	0	0	0
Any AEs	13 (100.0) 45	1 (25.0) 1	14 (82.4) 46
Severity of AEs
Mild	13 (100.0) 42	1 (25.0) 1	14 (82.4) 43
Moderate	2 (15.4) 3	0	2 (11.8) 3
Severe	0	0	0
AEs related to rIX-FP	0	0	0

rIX-FP, coagulation factor IX (recombinant), albumin fusion protein; N, number of subjects with AEs; AE, adverse events.